LE 300

Pricing Availability   Qty
Description: Potent and selective D1 antagonist
Chemical Name: 6,7,8,9,14,15-Hexahydro-7-methyl-5H-indolo[3,2-f][3]benzazecine
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Reviews
Literature (4)

Biological Activity for LE 300

LE 300 is a potent and selective dopamine D1 receptor antagonist (Ki values are 0.08 - 1.9 nM and 6 - 45 nM for D1 and D2 receptors respectively). Also displays moderate affinity for the 5-HT2A receptor (Ki = 20 nM). Active in vivo.

Compound Libraries for LE 300

LE 300 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for LE 300

M. Wt 290.41
Formula C20H22N2
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 274694-98-3
PubChem ID 4350931
InChI Key YEWGIGCYIAMFMA-UHFFFAOYSA-N
Smiles CN1CCC2=C(CC3=CC=CC=C3CC1)NC1=CC=CC=C21

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for LE 300

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
1eq. HCl 14.52 50
DMSO 29.04 100

Preparing Stock Solutions for LE 300

The following data is based on the product molecular weight 290.41. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.44 mL 17.22 mL 34.43 mL
5 mM 0.69 mL 3.44 mL 6.89 mL
10 mM 0.34 mL 1.72 mL 3.44 mL
50 mM 0.07 mL 0.34 mL 0.69 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for LE 300

Certificate of Analysis / Product Datasheet
Select another batch:

References for LE 300

References are publications that support the biological activity of the product.

El-Subbagh et al (2002) DA/serotonin receptor ligands: Part IV [1]: Synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and DA receptor ligands. Arch.Pharm. (Weinheim). 9 443 PMID: 12447918

Kassack et al (2002) Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar DA receptor antagonist. Naunyn Schmiedebergs Arch.Pharmacol. 366 543 PMID: 12444495

Witt et al (2000) 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for DA receptor antagonists. J.Med.Chem. 43 2079 PMID: 10821720


If you know of a relevant reference for LE 300, please let us know.

View Related Products by Target

View Related Products by Product Action

View all D1 and D5 Receptor Antagonists

Keywords: LE 300, LE 300 supplier, Potent, selective, dopamine, D1, antagonists, Dopamine, Receptors, dopaminergic, LE300, and, D5, 1674, Tocris Bioscience

2 Citations for LE 300

Citations are publications that use Tocris products. Selected citations for LE 300 include:

Cilz et al (2014) DArgic modulation of GABAergic transmission in the entorhinal cortex: concerted roles of α1 adrenoreceptors, inward rectifier K+, and T-type Ca2+ channels. Cereb Cortex 24 3195 PMID: 23843440

Gildea et al (2012) DA and angiotensin type 2 receptors cooperatively inhibit sodium transport in human renal proximal tubule cells. Hypertension 60 396 PMID: 22710646


Do you know of a great paper that uses LE 300 from Tocris? Please let us know.

Reviews for LE 300

There are currently no reviews for this product. Be the first to review LE 300 and earn rewards!

Have you used LE 300?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.